Capítulo 1793: Chapter 1267: Are There Really Only Six People? (Part 2)
As for the Tumor K Therapy project, the module redeveloped based on the new platform’s underlying database and algorithm library, has even achieved a modest but surprising improvent in selection efficiency and prediction accuracy compared to the original key indicators due to the targeted optimization of the algorithm for its data structure and computational features.
Thanks to Yang Ping’s foresight, this almost seamless transition greatly stabilized the laboratory’s morale and completely dispelled so people’s initial doubts about “dostic substitution.”
Looking at the completion of the entire platform in the laboratory, Yang Ping took a deep breath. He could now rest easy; block them, block them for years—he could research anything.
…
At this mont, at BG headquarters in Switzerland, the atmosphere felt oppressive, so oppressive it drove people to ntal breakdowns.
Only six! Are there really only six mbers in the R&D team?
The X-2 that left him and the entire BG elite team powerless, perhaps even set them up in a reverse technical trap, actually originated from a team of only six people.
Dr. Walker’s fingers began to tremble uncontrollably, the paper making subtle “rustling” sounds at his fingertips.
He couldn’t believe it! He abruptly flipped the file to the back, urgently searching for information on more auxiliary R&D teams, outsourcing partners, or international advisory groups.
But the intelligence departnt’s supplentary notes inford him with calm wording: all core theoretical breakthroughs, disruptive technology path designs, and decisive key experintal verifications were led and completed by this six-person core group. Other teams or personnel ntioned in the file were mostly responsible for executing standardized procedures they set and for administrative logistics support work.
Actually, all previous intelligence indicated that the team had only six people, at the ti he did not care, no one cared. He believed the intelligence description must be wrong, that these six people should be the decision-makers, not that the team was six people, but today’s intelligence has clarified this point: the entire team is just six people.
“Six people… this… this is impossible… absolutely impossible…” he murmured, his voice dry and hoarse, the color on his face faded visibly to a pallid white.
He, Dr. Walker, was leading BG Group’s enormous R&D team with hundreds of PhDs from the world’s top universities, equipped with automation equipnt and analytical instrunts worth billions of US Dollars, considered the world’s best, spending countless months, investing a trendous amount of money and resources that he himself was reluctant to precisely calculate, yet he couldn’t even replicate the superficial technology from the other side completely, and it was highly possible that from the beginning, they were miserably toyed with by a ticulously prepared, tailor-made “technical trap,” wasting endless ti and money in the wrong direction.
And the opposing team, which embarrassed him and Carl so much, made BG so passive, has a core that consists of only six people!
At this mont, his mind uncontrollably conjured up the image of Carl Mueller’s face, always carrying arrogance and indisputability, Gan Fengyi’s calmness bordering on cold, seemingly able to insight everything, and those talented researchers in his laboratory, overwheld and repeatedly failing, their eyes shifting from confidence to bewildernt… all the anger, grievance, self-doubt, and humiliation of a scientist’s dignity being trampled, at this mont, were thoroughly shattered and crushed by these simple, cold “six people” three words.
This was no longer simply a technology gap; this was a difference in cognitive dinsions, a generation gap in innovation!
“Ha-ha… ha-ha-ha…” Dr. Walker suddenly chuckled, the laughter initially suppressed, then becoming hoarse and bleak, echoing in the empty office, filled with the taste of despair and self-mockery.
He grabbed the heavy file on the table with all his strength and threw it forcefully on the ground, papers scattering everywhere. Then he held his head with both hands, fingers deeply buried in his already gray hair as if trying to remove the devastating information from his mind.
“This war is already lost.”
At this mont, he was more convinced than ever. Facing such opponents, BG’s all traditional, proud competitive thods—capital, patents, public opinion, and even disgraceful theft—were just scratching the surface, even exposing their own stupidity and clumsiness, accelerating their complete failure.
He sat weakly in the soft high-backed leather chair, gazing emptily at the ceiling, his eyes losing focus.
Deep in his heart, a thought he had deliberately suppressed for a long ti erged like a beast breaking out of a cage: perhaps the real future, the next fertile ground of science, does not lie within BG, this seemingly indestructible, splendid, yet internally corroded old fortress by power struggles, shortsighted comrcial interests, and bureaucratic air; but across the ocean, in that seemingly simple, harsh-conditioned yet full of primal vitality, unlimited possibilities, and pure research passion laboratory?
This thought filled him with a sense of fear and betrayal, but strangely, beneath this fear, there was a faint trace of relief he hadn’t experienced in a long ti.
As a scientist, shouldn’t he be happy?
Yang Ping has achieved what he couldn’t, gained what he didn’t, fulfilled his forr fantasies.
…
anwhile, on the other side of Earth.
Inside Yang Ping’s office, complex gene sequences and protein structure simulation diagrams displayed on the monitor in front of him.
Huang Jiacai sat on the sofa opposite him, with an open encrypted laptop on his lap, his expression graver than usual.
“Our partner law firms in Europe and Arica have almost simultaneously sent warnings; insiders close to us within the FDA and EMA have revealed that there are powerful industry forces actively lobbying, demanding the strictest review standards for pharmaceutical products based on wholly new, unverified technology platforms, especially technologies involving gene regulation and recombinant vaccine technologies like enhancers. Soone even proposed calling a special expert hearing to introduce regulations restricting this kind of high-risk drugs and vaccines from being marketed—we are still in the clinical trial phase, and they already are making such high-profile arrangents to prevent us from listing overseas.”
Yang Ping’s gaze moved from the screen to Huang Jiacai: “Going global is a good thing, but it’s not sothing we can completely control. What we can do is launch the best technology. If they don’t let us go to Europe and Arica in the future, it’s their loss, not much impact on us, the enormous dostic market is enough to support the subsequent developnt of this new technology. You must rember, valuable things are never begged for.” His tone revealed neither joy nor anger, just softly rhythmically tapping his fingers on the desktop.
“I understand, Professor!”
Huang Jiacai nodded.
“They’re not only exerting force in public opinion and regulation,” Huang Jiacai continued, “our international market team reports that their target range has expanded, not just our new technology and products, but all products of our Ruixing Alliance Enterprise are within the target range. In several key target markets in Southeast Asia and Latin Arica, originally smoothly progressing business negotiations suddenly stalled, influential local agents or partners started delaying signatures with various excuses, hinting at pressures from higher levels.”
“While stabilizing the dostic market, we will also learn how to compete with them. One day, we will go global, now we treat it as training.”
Yang Ping agreed: “It’s good that you have such ideas; the international market needs to be conquered, not begged for.”
User Comments
0 comments from readers